# US 2026/0007705 A1 · Probiotic compositions for production of dopamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007705 A1
- Document ID: US20260007705A1
- Status: Published application
- Kind: A1
- Application number: 19/329,122
- Filed: 2025-09-15
- Published: 2026-01-08
- Earliest claimed: 2017-09-22
- Assignees: Iowa State University Research Foundation, Inc.
- Applicants: Iowa State University Research Foundation, Inc.
- Inventors: Mark Lyte; Daniel Nicholas Villageliu
- Web page: https://patentgrep.com/patent/US20260007705A1

## CPC

- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12Q 1/02: involving viable microorganisms
- G01N 2500/10: involving cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention is directed to synbiotic compositions of probiotic strains and prebiotics, along with uses thereof for targeted human and animal applications, for example, in promoting health and well-being and/or treating therapeutic conditions. The present invention is also directed to methods of probiotic selection and detection of strains with the ability to produce neurochemicals in the gastrointestinal tract of a subject, providing a microbial endocrinology-based mechanism and approach for optimization of synbiotic delivery of a probiotic with a neurochemical precursor. Still further the present invention is directed to industrial applications for production of dopamine utilizing methods and media suitable for the same.

## Claims

### Claim 1

A synbiotic composition comprising:
a therapeutically effective amount of at least one probiotic strain; and
a therapeutically effective amount of a precursor or a co-factor of dopamine.

### Claim 2 (depends on 1)

The composition of claim 1, wherein therapeutically effective amount of the probiotic strain(s) is from about 104 CFU to about 1012 CFU.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said probiotic strain is a bacterial strain.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said bacterial strain is an Enterococcus spp.

### Claim 5 (depends on 3)

The composition of claim 3, wherein said bacterial strain is a Vagococcus spp.

### Claim 6 (depends on 3)

The composition of claim 3, wherein said bacterial strain is a Lactobacillus spp.

### Claim 7 (depends on 6)

The composition of claim 6, wherein said bacterial strain is Lactobacillus plantarum.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the therapeutically effective amount of the precursor of dopamine is from about 1 mg/kg to about 10 mg/kg.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said precursor is L-DOPA, or wherein said co-factor is pyridoxal phosphate.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the composition is in an oral dosage in liquid or solid form.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the precursor is a food source.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the precursor is L-DOPA and the food source is an herbal or plant source.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the herbal or plant source is Mucuna pruiens, Vicia faba, Phanera spp., Pillostigma spp., Canavalia spp., and/or Dalbergia spp.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the synbiotic composition is contained in a time release tablet or capsule.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the composition is an oral dosage in liquid or solid dosage form.
